

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 154 020 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

14.11.2001 Bulletin 2001/46

(51) Int Cl.7: **C12N 15/31, C12N 1/21,  
C07K 14/34**

(21) Application number: **01109457.0**

(22) Date of filing: **24.04.2001**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**

Designated Extension States:

**AL LT LV MK RO SI**

(30) Priority: **28.04.2000 JP 2000129167**

(71) Applicant: **Ajinomoto Co., Ltd.**

**Tokyo (JP)**

(72) Inventors:

- **Suga, Mikiko, Ajinomoto Co., Inc.**  
**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**

- **Asakura, Yoko, Ajinomoto Co., Inc.**

**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**

- **Mori, Yukiko, Ajinomoto Co., Inc.**

**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**

- **Ito, Hisao, Ajinomoto Co., Inc.**

**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**

- **Kurahashi, Osamu, Ajinomoto Co., Inc.**

**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**

(74) Representative: **HOFFMANN - EITLE**

**Patent- und Rechtsanwälte**

**Arabellastrasse 4**

**81925 München (DE)**

(54) **Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine**

(57) L-Arginine is produced by culturing a coryneform bacterium in which an arginine repressor involved in L-arginine biosynthesis is deleted by disrupting a

gene coding for the repressor, and which has L-arginine producing ability in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

**EP 1 154 020 A2**

**Description**

Field of the Invention

[0001] The present invention relates to a coryneform bacterium having an ability to produce L-arginine and a method for producing L-arginine using the bacterium. L-arginine is an industrially useful amino acid as an ingredient of liver function promoting agents, amino acid infusions, comprehensive amino acid pharmaceuticals and so forth.

Description of the Related Art

[0002] Conventional L-arginine production by fermentation has been performed by utilizing wild-type strains of coryneform bacteria; coryneform bacteria resistant to certain agents including sulfa drugs, 2-thiazolealanine,  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid and the like; coryneform bacteria exhibiting auxotrophy for L-histidine, L-proline, L-threonine, L-isoleucine, L-methionine, or L-tryptophan in addition to the resistance to 2-thiazolealanine (Japanese Patent Laid-open No. 54-44096); coryneform bacteria resistant to ketomalonic acid, fluoromalonic acid, or monofluoroacetic acid (Japanese Patent Laid-open No. 57-18989); coryneform bacteria resistant to argininol (Japanese Patent Laid-open No. 62-24075); coryneform bacteria resistant to X-guanidine (X represents a derivative of fatty acid or aliphatic chain, Japanese Patent Laid-open No. 2-186995) or the like.

[0003] On the other hand, there have also been disclosed methods for producing L-arginine utilizing recombinant DNA techniques. That is, there has been disclosed a method for producing L-arginine by utilizing a microorganism belonging to the genus *Corynebacterium* or *Brevibacterium* which is made to harbor a recombinant DNA comprising a vector DNA and a DNA fragment containing genes for acetylornithine deacetylase, N-acetylglutamic acid- $\alpha$ -semialdehyde dehydrogenase, N-acetyl glutamokinase, and argininosuccinase derived from a microorganism belonging to the genus *Escherichia* (Japanese Patent Publication No. 5-23750).

[0004] Further, as for coryneform bacteria, it has been elucidated that synthesis of some enzymes of the L-arginine biosynthetic system is repressed by L-arginine. Furthermore, it was reported that, while some of enzymes of L-arginine biosynthetic system were repressed by L-arginine, the repression of these enzymes by L-arginine was canceled in mutant strains of coryneform bacteria showing improved L-arginine accumulation amounts (*Agric. Biol. Chem.*, 43(1), 105, 1979).

[0005] Meanwhile, as for *Escherichia coli*, a repressor of L-arginine biosynthetic system and a gene coding for the repressor were identified (*Proc. Natl. Acad. Sci. U.S.A.* (1987), 84(19), 6697-701), and binding interactions of the repressor protein and various genes of L-arginine biosynthetic system were also investigated (*Proc. Natl. Acad. Sci. U.S.A.* (1987), 84(19), 6697-701, *J. Mol. Biol.* (1992), 226, 367-386).

[0006] However, any repressor proteins of the L-arginine biosynthetic system have not been identified in coryneform bacteria. While a nucleotide sequence of the repressor protein gene (*argR*) and an amino acid sequence assumed to be encoded thereby are registered in a gene database, GenBank (AF049897), the gene is considered to be designated *argR* because of the homology between the aforementioned amino acid sequence and known arginine repressors.

Summary of the Invention

[0007] As described above, although a repressor protein of the L-arginine biosynthetic system of coryneform bacteria and a gene thereof are expected, the repressor protein itself has not been identified and its functions and so forth are not elucidated at all. Therefore, an object of the present invention is to identify the repressor of the L-arginine biosynthesis in coryneform bacteria, and improve L-arginine productivity of coryneform bacteria.

[0008] The inventors of the present invention isolated a homologue of the gene registered as *argR* in the gene database (GenBank accession AF049897) from a coryneform bacterium, and found that, if this gene was amplified in coryneform bacteria, L-arginine producing ability was decreased, and on the other hand, if the gene was disrupted, the L-arginine producing ability was improved, to confirm that the L-arginine biosynthesis is repressed by a repressor in coryneform bacteria like *Escherichia coli* and the aforementioned gene registered as *argR* codes for the repressor.

Thus, the present invention was accomplished.

[0009] That is, the present invention provides the followings.

(1) A coryneform bacterium in which an arginine repressor does not function in a normal manner, and which has L-arginine producing ability.

(2) The coryneform bacterium according to (1), wherein the arginine repressor does not function in a normal manner due to disruption of a gene coding for the arginine repressor on a chromosome of the bacterium.

(3) The coryneform bacterium according to (2), wherein the arginine repressor has the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence showing homology to the amino acid sequence.

(4) A method for producing L-arginine, which comprises culturing a coryneform bacterium according to any one of (1) to (3) in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

[0010] In the present invention, the "arginine repressor" refers to a protein that has an effect of repressing the L-arginine biosynthesis, and if expression amount of the gene that codes for the protein increases in coryneform bacteria, L-arginine producing ability will be reduced, and if the expression amount decreases or the protein disappears, the L-arginine producing ability will be improved. Hereafter, the gene coding for the arginine repressor is also called *argR* gene. Further, the "L-arginine producing ability" used in the present invention refers to an ability of the microorganism of the present invention to accumulate L-arginine in a medium, when it is cultured in the medium.

[0011] According to the present invention, L-arginine producing ability of coryneform bacteria having the L-arginine producing ability can be improved.

#### Brief Explanation of the Drawings

[0012] Fig. 1 shows the construction process of plasmid pK1.

[0013] Fig. 2 shows the construction process of plasmid pSFK6.

[0014] Fig. 3 shows the construction process of plasmid pSFKT2.

[0015] Hereafter, the present invention will be explained in detail.

[0016] The microorganism of the present invention is a coryneform bacterium having L-arginine producing ability, in which arginine repressor does not function in a normal manner. The coryneform bacterium of the present invention may be a microorganism having the L-arginine producing ability because an arginine repressor does not function in a normal manner in it, or a microorganism bred so that the arginine repressor should not function in a normal manner in it. Alternatively, it may be a microorganism that is bred so that the arginine repressor should not function in a normal manner in it and then imparted with the L-arginine producing ability.

[0017] The coryneform bacteria include bacteria having been hitherto classified into the genus *Brevibacterium* but united into the genus *Corynebacterium* at present (*Int. J. Syst. Bacteriol.*, 41, 255 (1981)), and include bacteria belonging to the genus *Brevibacterium* closely relative to the genus *Corynebacterium*. Examples of such coryneform bacteria include the followings.

*Corynebacterium acetoacidophilum*  
*Corynebacterium acetoglutamicum*  
*Corynebacterium alkanolyticum*  
*Corynebacterium callunae*  
*Corynebacterium glutamicum*  
*Corynebacterium lilium* (*Corynebacterium glutamicum*)  
*Corynebacterium melassecola*  
*Corynebacterium thermoaminogenes*  
*Corynebacterium herculis*  
*Brevibacterium divaricatum* (*Corynebacterium glutamicum*)  
*Brevibacterium flavum* (*Corynebacterium glutamicum*)  
*Brevibacterium immariophilum*  
*Brevibacterium lactofermentum* (*Corynebacterium glutamicum*)  
*Brevibacterium roseum*  
*Brevibacterium saccharolyticum*  
*Brevibacterium thiogenitalis*  
*Brevibacterium album*  
*Brevibacterium cerinum*  
*Microbacterium ammoniaphilum*

[0018] While the coryneform bacteria that have the L-arginine-producing ability are not particularly limited so long as they have the L-arginine-producing ability, they include, for example, wild-type strains of coryneform bacteria; coryneform bacteria resistant to certain agents including sulfa drugs, 2-thiazolealanine,  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid and the like; coryneform bacteria exhibiting auxotrophy for L-histidine, L-proline, L-threonine, L-isoleucine, L-methionine, or L-tryptophan in addition to the resistance to 2-thiazolealanine (Japanese Patent Laid-open No. 54-44096); coryneform bacteria resistant to ketomalonic acid, fluoromalonic acid, or monofluoroacetic acid (Japanese Patent Laid-open No. 57-18989); coryneform bacteria resistant to argininol (Japanese Patent Laid-open No. 62-24075); coryneform bacteria resistant to X-guanidine (X represents a derivative of fatty acid or aliphatic chain, Japanese Patent Laid-open

No. 2-186995) and the like.

[0019] Specifically, the following strains can be exemplified.

*Brevibacterium flavum* AJ11169 (BP-6892)  
*Corynebacterium glutamicum* AJ12092 (FERM BP-6906)  
*Brevibacterium flavum* AJ11336 (FERM BP-6893)  
*Brevibacterium flavum* AJ11345 (FERM BP-6894)  
*Corynebacterium glutamicum* AJ12430 (FERM BP-2228)

[0020] The AJ11169 strain and the AJ12092 strain are the 2-thiazolealanine resistant strains mentioned in Japanese Patent Laid-open No. 54-44096, the AJ11336 strain is the strain having argininosuccinate resistance and sulfadiazine resistance mentioned in Japanese Patent Publication No. 62-24075, the AJ11345 strain is the strain having argininosuccinate resistance, 2-thiazolealanine resistance, sulfaguanidine resistance, and exhibiting histidine auxotrophy mentioned in Japanese Patent Publication No. 62-24075, and the AJ12430 strain is the strain having octylguanidine resistance and 2-thiazolealanine resistance mentioned in Japanese Patent Laid-open No. 2-186995.

[0021] AJ11169 was deposited on August 3, 1977 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently National Institute of Bioscience and Human Technology, National Institute of Advanced Industrial Science and Technology, Ministry of Economy, Trade and Industry)(zip code: 305-8566, 1-3 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan), as deposition number of FERM P-4161, and transferred from the original deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6892.

[0022] AJ12092 was deposited on September 29, 1983 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number of FERM P-7273, and transferred from the original deposit to international deposit based on Budapest Treaty on October 1, 1999, and has been deposited as deposition number of FERM BP-6906.

[0023] AJ11336 was deposited on April 25, 1979 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number of FERM P-4939, and transferred from the original deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6893.

[0024] AJ11345 was deposited on April 25, 1979 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number of FERM P-4948, and transferred from the original deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6894.

[0025] AJ12430 was deposited on December 26, 1988 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology of Ministry, International Trade and Industry based on Budapest Treaty, as deposition number of FERM BP-2228.

[0026] The coryneform bacterium whose arginine repressor does not function in a normal manner can be obtained by modifying its *argR* gene so that the activity of the arginine repressor should be reduced or eliminated, or the transcription of the *argR* gene should be reduced or eliminated. Such a coryneform bacterium can be obtained by, for example, replacing the chromosomal *argR* gene with an *argR* gene that does not function in a normal manner (occasionally referred to as "disrupted *argR* gene" hereinafter) through, for example, homologous recombination based on genetic recombination techniques (Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press (1972); Matsuyama, S. and Mizushima, S., *J. Bacteriol.*, 162, 1196 (1985)).

[0027] In the homologous recombination, when a plasmid carrying a sequence exhibiting homology with a chromosomal sequence or the like is introduced into a corresponding bacterial cell, recombination occurs at a site of the homologous sequence at a certain frequency, and thus the introduced plasmid as a whole is integrated into the chromosome. Then, by causing recombination again at the site of the homologous sequence in the chromosome, the plasmid may be removed from the chromosome. However, depending on the position at which the recombination is caused, the disrupted gene may remain on the chromosome, while the original normal gene may be removed from the chromosome together with the plasmid. By selecting such a bacterial strain, a bacterial strain in which the normal *argR* gene is replaced with a disrupted *argR* gene can be obtained.

[0028] Such a gene disruption technique based on the homologous recombination has already been established, and a method utilizing a linear DNA, method utilizing temperature sensitive plasmid or the like can be used therefor. The *argR* gene can also be disrupted by using a plasmid that contains the *argR* gene inserted with a marker gene such as drug resistance gene, and cannot replicate in a target cell of the coryneform bacterium. That is, in a transformant that has been transformed with such a plasmid and hence acquired drug resistance, the marker gene is integrated in a chromosome DNA. It is likely that this marker gene has been integrated by homologous recombination of the *argR* gene present at the both sides of the marker with the *argR* on the chromosome, and therefore a gene-disrupted strain

can efficiently be selected.

[0029] Specifically, a disrupted *argR* gene used for the gene disruption can be obtained by deletion of a certain region of *argR* gene by means of digestion with restriction enzyme(s) and religation; by insertion of another DNA fragment (marker gene etc.) into the *argR* gene, by introducing substitution, deletion, insertion, addition or inversion of one or more nucleotides in a nucleotide sequence of coding region of *argR* gene, its promoter region or the like by means of site-specific mutagenesis (Kramer, W. and Frits, H. J., *Methods in Enzymology*, 154, 350 (1987)) or treatment with a chemical reagent such as sodium hyposulfite and hydroxylamine (Shortle, D. and Nathans, D., *Proc. Natl. Acad. Sci. U.S.A.*, 75, 270(1978)) or the like, so that the activity of the encoded repressor should be reduced or eliminated, or transcription of the *argR* gene should be reduced or eliminated. Among these embodiments, a method utilizing deletion of a certain region of the *argR* gene by digestion with a restriction enzyme and religation, or insertion of another DNA fragment into the *argR* gene is preferred in view of reliability and stability.

[0030] A plasmid for the *argR* gene disruption can be produced by performing PCR (polymerase chain reaction) using a plasmid containing the *argR* gene and its flanking regions as a template and primers corresponding the terminal portions or flanking regions of the *argR* gene to amplify a portion except for an internal portion or the whole portion of the *argR* gene, and cyclizing the obtained amplified product. In the examples mentioned hereinafter, the *argR* gene was disrupted by this method.

[0031] The *argR* gene can be obtained from a chromosomal DNA of a coryneform bacterium by PCR using oligonucleotides prepared based on known nucleotide sequences of the *argR* gene as primers. The *argR* gene can also be obtained from a chromosome DNA library of a microorganism which has a purine operon by a hybridization technique using an oligonucleotide prepared based on a known nucleotide sequence of the *argR* gene as a probe. For the purpose of the present invention, because the *argR* gene is used for preparing a disrupted *argR* gene, it is not necessarily required to contain the full length, and it may contain a length required to cause gene disruption.

[0032] The origin of the *argR* gene is not particularly limited, so long as it has such a degree of homology that it should cause homologous recombination with the *argR* gene of coryneform bacteria. Specifically, the *argR* gene of the *Brevibacterium flavum*, which has the nucleotide sequence shown in SEQ ID NO: 17, and the *argR* gene of *Corynebacterium glutamicum* (GenBank accession AF049897) can be mentioned as the *argR* genes of coryneform bacteria. These *argR* genes are highly homologous, and it is considered that even an *argR* gene of coryneform bacterium of a genus or species different from that of a coryneform bacterium of which *argR* gene is to be disrupted may also be used for the gene disruption.

[0033] In the present invention, the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence exhibiting homology to the amino acid sequence means an amino acid sequence that is encoded by an *argR* gene having such a degree of homology that it should cause homologous recombination with the *argR* gene coding to the amino acid sequence shown in SEQ ID NO: 18 (for example, an *argR* gene having the nucleotide sequence shown in SEQ ID NO: 17).

[0034] As the primers used for PCR, any primers that allow amplification of the *argR* gene can be used. Specific examples thereof include the oligonucleotides having the nucleotide sequences shown in SEQ ID NOS: 19 and 20.

[0035] Further, examples of marker gene include drug resistance genes such as a kanamycin resistance gene. A kanamycin resistance gene can be obtained by PCR amplification from a known plasmid containing a kanamycin resistance gene of *Streptococcus faecalis*, for example, pDG783 (Anne-Marie Guerout-Fleury *et al.*, *Gene*, 167, 335-337 (1995)).

[0036] When a drug resistance gene is used as the marker gene, an *argR* gene-disrupted strain can be obtained by inserting the drug resistance gene into a suitable site of the *argR* gene carried by a plasmid, transforming a microorganism with the plasmid, and selecting a drug resistant transformant. Disruption of *argR* gene on a chromosome can be confirmed by analyzing the *argR* gene or the marker gene on the chromosome by Southern blotting, PCR, or the like. Integration of the kanamycin resistance gene into a chromosomal DNA can be confirmed by PCR using primers that allow amplification of the kanamycin resistance gene (e.g., oligonucleotides having nucleotide sequences shown in SEQ ID NOS: 1 and 2).

[0037] L-arginine can be efficiently produced by culturing a coryneform bacterium having L-arginine producing ability obtained as described above, in which an arginine repressor does not function in a normal manner, in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

[0038] The medium to be used may be selected from well-known media conventionally used for fermentative production of amino acids utilizing microorganisms. That is, it may be a usual medium that contains a carbon source, nitrogen source, inorganic ions, and other organic ingredients as required.

[0039] As the carbon source, there can be used saccharides such as glucose, sucrose, lactose, galactose, fructose or starch hydrolysate, alcohols such as glycerol or sorbitol, or organic acids such as fumaric acid, citric acid or succinic acid.

[0040] As the nitrogen source, there can be used inorganic ammonium salts such as ammonium sulfate, ammonium chloride or ammonium phosphate, organic nitrogen such as soybean protein hydrolysate, ammonia gas, aqueous

ammonia and so forth.

[0041] It is desirable to add required substances such as vitamin B<sub>1</sub> and L-homoserine, yeast extract and so forth to the medium in appropriate amounts as organic trace nutrients. Other than the above, potassium phosphate, magnesium sulfate, iron ion, manganese ion and so forth are added in small amounts as required.

[0042] The culture is preferably carried out under an aerobic condition for 1-7 days. The culture temperature is preferably controlled to be 24°C to 37°C, and pH is preferably controlled to be 5-9 during the culture. Inorganic or organic, acidic, alkaline substances, or ammonia gas and so forth can be used for pH adjustment. L-arginine can be collected from the fermentation broth usually by a combination of well-known techniques such as ion exchange resin techniques and other techniques.

#### Best Mode for Carrying out the Invention

[0043] Hereafter, the present invention will be explained more specifically with reference to the following examples.

#### Example 1: Constructions of shuttle vector for *Escherichia coli* and coryneform bacteria and temperature sensitive vector

[0044] First, a vector for introducing an *argR* gene into coryneform bacteria and a temperature sensitive vector for producing an *argR* deficient strain of coryneform bacterium were constructed.

##### <1> Construction of vector having drug resistance gene of *Streptococcus faecalis*

[0045] The kanamycin resistance gene of *Streptococcus faecalis* was amplified by PCR from a known plasmid containing the gene. The nucleotide sequence of the kanamycin resistance gene of *Streptococcus faecalis* has already been elucidated (Trieu-Cuot, P. and Courvalin, P.: *Gene*, 23 (3), 331-341 (1983)). Based on this sequence, the primers shown in SEQ ID NOS: 1 and 2 were synthesized, and PCR was performed by using pDG783 (Anne-Marie Guerout-Fleury, *et al.*, *Gene*, 167, 335-337 (1995)) as a template to amplify a DNA fragment containing the kanamycin resistance gene and its promoter.

[0046] The aforementioned DNA fragment was purified by using SUPREC02 produced by Takara Shuzo Co., Ltd., and then completely digested with restriction enzymes *Hind*III and *Hind*I to be blunt-ended. The blunt-ending was performed by using Blunting Kit produced by Takara Shuzo Co., Ltd. This DNA fragment was mixed with a DNA fragment obtained by purification and blunt-ending of an amplification product of PCR performed by using the primers shown in SEQ ID NOS: 3 and 4 and pHSG399 (see S. Takeshita, *et al.*: *Gene*, 61, 63-74 (1987)) as a template, and ligated both fragments. The ligation was performed by using DNA Ligation Kit Ver. 2 produced by Takara Shuzo Co., Ltd. Competent cells of *Escherichia coli* JM109 (produced by Takara Shuzo Co., Ltd.) were transformed with the ligated DNA, plated on L medium (10 g/L of Bacto trypton, 5 g/L of Bacto yeast extract, 5 g/L of NaCl, 15 g/L of agar, pH 7.2) containing 10 µg/ml of IPTG (isopropyl-β-D-thiogalactopyranoside), 40 µg/ml of X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) and 25 µg/ml of kanamycin, and cultured overnight. The emerged blue colonies were picked up, and separated into single colonies to obtain transformant strains.

[0047] Plasmids were prepared from the transformant strains by the alkali method (Seibutsu Kagaku Jikkensyo (Text for Bioengineering Experiments), Edited by the Society for Bioscience and Bioengineering, Japan, p.105, Baifukan, 1992), and restriction maps were prepared. One having a restriction map equivalent to that of Fig. 1 was designated as pK1. This plasmid is stably harbored in *Escherichia coli*, and imparts kanamycin resistance to a host. Moreover, since it contains the *lacZ'* gene, it is suitably used as a cloning vector.

##### <2> Construction of shuttle vector pSFK6

[0048] As a material for obtaining a temperature sensitive replication control region, a plasmid vector autonomously replicable in both of *Escherichia coli* cells and coryneform bacteria cells was prepared. The plasmid pAM330 extracted from *Brevibacterium lactofermentum* ATCC13869 [see Japanese Patent Publication Laid-open (Kokai) No. 58-67699] was completely digested with a restriction enzyme *Hind*III, and blunt-ended. This fragment was ligated to a fragment obtained by completely digesting the aforementioned pK1 with a restriction enzyme *Bsa*AI. *Brevibacterium lactofermentum* ATCC13869 was transformed with the ligated DNA. The transformation was performed by the electric pulse method [see Japanese Patent Publication Laid-open (Kokai) No. 2-207791]. Transformants were selected on an M-CM2B plate (10 g/L of polypeptone, 10 g/L of yeast extract, 5 g/L of NaCl, 10 µg/L of biotin, 15 g/L of agar, pH 7.2) containing 25 µg/ml of kanamycin. After cultivation for 2 days, colonies were picked up, and separated into single colonies to obtain the transformants. Plasmid DNAs were prepared from the transformants, and restriction maps were prepared. One having the same restriction map as that of Fig. 2 was designated as pSFK6. This plasmid is auto-

mously replicable in both of *Escherichia coli* and coryneform bacteria, and imparts kanamycin resistance to a host.

### <3> Construction of a plasmid having temperature sensitive replication control region

[0049] pSFK6 was treated with hydroxylamine *in vitro*. The hydroxylamine treatment was performed according to a known method [see, for example, G.O. Humpherys, *et al.*, *Molec. Gen. Genet.*, 145, 101-108 (1976)]. DNA undergone the treatment was collected and used for transformation of *Brevibacterium lactofermentum* ATCC13869 strain. The transformants were selected at a low temperature (25°C) on a CM2B plate containing 25 µg/ml of kanamycin. The appeared transformants were replicated to a similar selection plate, and cultured at an elevated temperature (34°C). One strain that could not grow on the selection plate containing kanamycin at the elevated temperature was obtained. From this strain, a plasmid was recovered and designated as p48K.

### <4> Determination of nucleotide sequence of temperature sensitive replication control region

[0050] Nucleotide sequences of replication control region segments in the plasmid pSFK6 having a wild-type replication control region and the plasmid p48K having a temperature sensitive replication control region were determined. The nucleotide sequences were determined on a fully automatic sequencer, ABI310 (ABI), by using DNA Sequencing Kit from ABI. As a result, it was found that there were 6 nucleotide substitutions between the wild-type replication control region and the temperature sensitive replication control region. The nucleotide sequence of the temperature sensitive replication control region segment contained in pSFK6 (derived from full sequence of pAM330), which functions in coryneform bacteria, is shown in SEQ ID NO: 5, and the nucleotide sequence of the temperature sensitive replication control region segment contained in p48K, which functions in coryneform bacteria, is shown in SEQ ID NO: 7. Further, the amino acid sequences encoded by ORFs contained in these nucleotide sequences are shown in SEQ ID NOS: 6 and 8. In the temperature sensitive replication control region, the 1255th C is mutated to T, the 1534th C to T, the 1866th G to A, the 2058th G to A, the 2187th C to T and 3193rd G to A. Among these, only the mutation at 1534th position is accompanied by an amino acid mutation, and causes substitution of serine for proline.

### <5> Construction of shuttle vectors having temperature sensitive mutation

[0051] Each one of the six mutations of p48K was introduced into a shuttle vector pSFK6 (see Fig. 3). The introduction of the mutations was performed by a known method [Mikaelian, I., Sergeant, A., *Nucleic Acids Res.*, 20, 376 (1992)]. Specific procedure will be mentioned below. In order to introduce the mutation of 1534th C to T, PCR was performed by using a combination of the primers shown in SEQ ID NOS: 9 and 10 (primers 9 and 10), and a combination of the primers shown in SEQ ID NOS: 11 and 12 (primers 11 and 12), and pAM330 as a template. Each of the obtained amplification products was purified by subjecting them to agarose gel electrophoresis, and collecting them from the gel. The collection of the DNA fragments from the gel was performed by using EASYTRAP Ver.2 (Takara Shuzo Co., Ltd.). The purified DNAs were mixed in a molar ratio of 1:1, and used as a template for PCR performed by using the primers shown SEQ ID NOS: 13 and 14 (primers 13 and 14). The amplification product was fully digested with a restriction enzyme MluI, and subjected to agarose gel electrophoresis to recover a DNA fragment of about 3.2 kb. Similarly, pSFK6 was also completely digested with a restriction enzyme MluI, and subjected to agarose gel electrophoresis to recover a DNA fragment of about 3.8 kb. The obtained DNA fragments were mixed and ligated, and used to transform competent cells of *Escherichia coli* JM109 (Takara Shuzo Co., Ltd.). The cells were applied on L medium containing 25 µg/ml of kanamycin, and cultured overnight. The appeared colonies were picked up, and isolated single colonies to obtain transformant strains. A plasmid was prepared from the transformant strains by the alkaline method, and the nucleotide sequence of the plasmid was determined to confirm that 1534th C in the sequence shown in SEQ ID NO: 5 was mutated to T. This plasmid was designated as pSFKT2 (Fig. 3).

### Example 2: Cloning of *argR* gene and amplification effect thereof in coryneform bacteria

[0052] PCR was performed by using chromosome DNA of the *Brevibacterium flavum* wild strain 2247 (AJ14067) as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 15 (sequence of the nucleotide numbers 1717-1741 in SEQ ID NO: 17) and SEQ ID NO: 16 (sequence complementary to the sequence of the nucleotide numbers 2386-2362 in SEQ ID NO: 17) as primers (Primers 15 and 16). PCR was performed for 30 cycles with each cycle consisting of reactions at 98°C for 10 seconds, 58°C for 1 minute and 72°C for 3 minutes by using Pyrobest DNA polymerase (Takara Shuzo Co., Ltd.). The obtained amplified fragment was inserted into the *Sma*I site of the shuttle vector pSFK6 obtained in Example 1 to obtain plasmid pWR autonomously replicable in coryneform bacteria.

[0053] In order to investigate the amplification effect of *argR* gene in L-arginine producing coryneform bacteria, pWR

was introduced into the AJ113455 strain (FERM BP-6894), which is an L-arginine producer of *Brevibacterium flavum*. The plasmid was introduced by the electric pulse method (Japanese Patent Laid-open No. 2-207791). A transformant was selected as a kanamycin resistant strain on CM2G agar medium (containing 5 g of glucose, 5 g of NaCl and 15 g of agar in 1 L of pure water, pH 7.2) containing 25 µg/ml of kanamycin to obtain AJ11345/pWR. As a control, pSFK6

was similarly introduced into the AJ113455 strain to obtain a transformant AJ11345/pSFK6. [0054] Each of the aforementioned strains was plated on an agar medium containing 0.5 g/dl of glucose, 1 g/dl of polypeptone, 1 g/dl of yeast extract and 0.5 g/dl of NaCl, and cultured at 31.5°C for 20 hours. One platinum loop of the obtained cells were inoculated into a medium containing 4 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.1 g/dl of KH<sub>2</sub>PO<sub>4</sub>, 0.04 g/dl of MgSO<sub>4</sub>, 0.001 g/dl of FeSO<sub>4</sub>, 0.001 g/dl of MnSO<sub>4</sub>, 5 µg/dl of vitamin B<sub>1</sub>, 5 µg/dl of biotin and soybean protein hydrolysate (45 mg/dl as N amount), and cultured in a flask at 31.5°C for 50 hours with shaking. Accumulation amount of L-arginine (concentration, g/dl) in each culture broth was measured. The results are shown in Table 1. As a result, the *argR*-amplified strain hardly accumulated L-arginine. This demonstrated that the *argR* gene product functioned as an arginine repressor.

Table 1

Strain	L-Arginine accumulation amount (g/dl)
AJ11345/pSFK6	1.3
AJ11345/pWR	0.2

[0055] The result of nucleotide sequencing for the inserted fragment cloned in pWR is shown in SEQ ID NO: 17. An amino acid sequence that may be encoded by that nucleotide sequence is shown in SEQ ID NO: 18.

#### Example 3: Construction of *argR*-disrupted strain of coryneform bacterium and effect of deletion of arginine repressor

##### <1> Construction of plasmid for *argR* disruption

[0056] PCR was performed by using chromosome DNA of a wild strain of *Brevibacterium flavum*, 2247 strain (AJ14067), as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 19 (sequence of the nucleotide numbers 4-28 in SEQ ID NO: 17) and SEQ ID NO: 20 (sequence complementary to the sequence of the nucleotide numbers 4230-4211 in SEQ ID NO: 17) as primers (Primers 19 and 20). PCR was performed for 30 cycles with each cycle consisting of reactions at 98°C for 10 seconds, 58°C for 1 minute and 72°C for 3 minutes by using Pyrobest DNA polymerase (Takara Shuzo Co., Ltd.). The obtained amplified fragment was inserted into the *Sma*I site in a multicloning site of cloning vector pHSG399.

[0057] In order to delete the whole ORF considered to encode the arginine repressor from the inserted DNA fragment, PCR was performed by using the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 21 (sequence of the nucleotide numbers 2372-2395 in SEQ ID NO: 17) and SEQ ID NO: 22 (sequence complementary to the sequence of the nucleotide numbers 1851-1827 in SEQ ID NO: 17) as primers (Primers 21 and 22) and pHSG399 inserted with the amplified fragment as a template. pssER was constructed by self-ligation of the PCR product.

[0058] Then, a fragment obtained by digesting pssER with restriction enzymes *Sma*I and *Sa*I and the temperature sensitive plasmid pSFKT2 obtained in Example 1 and digested with *Sma*I and *Sa*I were ligated to obtain plasmid pssERT for *argR* disruption whose autonomous replication ability in coryneform bacteria became temperature sensitive.

##### <2> Construction of arginine repressor deficient strain of coryneform bacterium by homologous recombination

[0059] The plasmid pssERT obtained as described above was introduced into the *Brevibacterium lactofermentum* AJ13029 strain (FERM BP-5189). The plasmid was introduced by the electric pulse method (Japanese Patent Laid-open No. 2-207791). Because autonomous replication ability of this plasmid is temperature sensitive in *Brevibacterium lactofermentum*, only strains in which this plasmid was incorporated into the chromosome by homologous recombination could be selected as kanamycin resistant strains at 34°C, which was a temperature that did not allow replication of the plasmid. Strains in which the plasmid for *argR* disruption was incorporated into a chromosome were selected as kanamycin resistant strains on a CM2G plate (containing 10 g/L of polypeptone, 10 g/L of yeast extract, 5 g/L of glucose, 5 g/L of NaCl and 15 g/L of agar in 1 L of water, pH 7.2) containing 25 µg/ml of kanamycin. At this stage, the normal *argR* gene derived from the chromosome and the *argR* gene derived from the plasmid in which ORF was deleted were present in tandem at the both sides of the plasmid portion on the chromosome.

[0060] Then, the recombinant strains were allowed to cause homologous recombination again, and strains that became kanamycin sensitive at 34°C, which was a temperature that did not allow the plasmid replication, were selected



## EP 1 154 020 A2

as strains in which one of the *argR* genes was deleted. These strains include strains in which the normal *argR* gene remained on the chromosome and strains in which the disrupted *argR* gene remained on the chromosome. From these strains, a strain having only the disrupted *argR* gene was selected. An *argR* gene on the chromosome is determined to be the disrupted type by preparing chromosome of a strain that became kanamycin sensitive at 34°C, performing PCR utilizing the chromosome as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NOS: 19 and 20 as primers (Primers 19 and 20), and confirming that the PCR product was shorter by about 600 bp than that obtained by similarly performing PCR utilizing chromosome derived from the parent strain as a template. [0061] Direct sequencing of the PCR product of the *argR*-disrupted strain selected as described above was performed to confirm that the *argR* gene was disrupted as desired, and thus AJ13029AR strain was obtained.

### <3> Production of L-arginine with *argR*-disrupted strain

[0062] The AJ13029AR strain was plated on an agar medium containing 0.5 g/dl of glucose, 1 g/dl of polypeptone, 1 g/dl of yeast extract and 0.5 g/dl of NaCl, and cultured at 31.5°C for 20 hours. One platinum loop of the obtained cells were inoculated into a medium containing 3 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.1 g/dl of KH<sub>2</sub>PO<sub>4</sub>, 0.04 g/dl of MgSO<sub>4</sub>, 0.001 g/dl of FeSO<sub>4</sub>, 0.001 g/dl of MnSO<sub>4</sub>, 300 µg/dl of vitamin B<sub>1</sub>, 200 µg/dl of biotin and soybean protein hydrolysate (165 mg/dl as N amount) and adjusted to pH 7.0 with NaOH, and cultured at 31.5°C for 24 hours as seed culture.

[0063] The above seed culture broth was inoculated in an amount of 1 ml into a medium containing 4 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.5 g/dl of KH<sub>2</sub>PO<sub>4</sub>, 0.04 g/dl of MgSO<sub>4</sub>, 0.001 g/dl of FeSO<sub>4</sub>, 0.01 g/dl of MnSO<sub>4</sub>, 5 µg/dl of vitamin B<sub>1</sub>, 5 µg/dl of biotin and soybean protein hydrolysate (45 mg/dl as N amount) and adjusted to pH 7.0 with KOH, and cultured in a flask at 31.5°C for 50 hours with shaking. Accumulation amount of L-arginine (concentration, mg/dl) in culture broth of each strain was measured. The results are shown in Table 2. As a result, the *argR*-disrupted strain accumulated L-arginine in a markedly larger amount compared with the parent strain.

Table 2

Strain	L-Arginine accumulation amount (mg/dl)
AJ13029	20
AJ13029AR	120

(Explanation of Sequence Listing)

### [0064]

SEQ ID NO: 1: primer for amplification of kanamycin resistance gene of *Streptococcus faecalis*  
 SEQ ID NO: 2: primer for amplification of kanamycin resistance gene of *Streptococcus faecalis*  
 SEQ ID NO: 3: primer for amplification of vector portion of pHSG399  
 SEQ ID NO: 4: primer for amplification of vector portion of pHSG399  
 SEQ ID NO: 5: nucleotide sequence of replication control region of pSFK6  
 SEQ ID NO: 6: amino acid sequence that may be encoded by ORF in pSFK6  
 SEQ ID NO: 7: nucleotide sequence of replication control region of p48K  
 SEQ ID NO: 8: amino acid sequence that may be encoded by ORF in p48K  
 SEQ ID NO: 9: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6  
 SEQ ID NO: 10: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6  
 SEQ ID NO: 11: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6  
 SEQ ID NO: 12: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6  
 SEQ ID NO: 13: primer for 2nd PCR for introducing mutation of 1534th C to T into pSFK6  
 SEQ ID NO: 14: primer for 2nd PCR for introducing mutation of 1534th C to T into pSFK6  
 SEQ ID NO: 15: primer for *argR* gene amplification  
 SEQ ID NO: 16: primer for *argR* gene amplification  
 SEQ ID NO: 17: nucleotide sequence of DNA fragment containing *argR* gene  
 SEQ ID NO: 18: amino acid sequence that may be encoded by the above DNA fragment  
 SEQ ID NO: 19: primer for *argR* gene amplification  
 SEQ ID NO: 20: primer for *argR* gene amplification  
 SEQ ID NO: 21: primer for amplifying portions other than *argR* gene ORF of plasmid containing *argR* gene  
 SEQ ID NO: 22: primer for amplifying portions other than *argR* gene ORF of plasmid containing *argR* gene

SEQUENCE LISTING

5 <110> Ajinomoto Co., Inc.

<120> Arginine Repressor Deficient Stain of Coryneform Bacterium and  
10 Method for Producing L-Arginine

<130> OP1018

15 <140>  
<141> 2001-04-

20 <150> JP2000-129167  
<151> 2000-04-28

<160> 22

25 <170> PatentIn Ver. 2.0

30 <210> 1  
<211> 32  
<212> DNA  
<213> Artificial Sequence

35 <220>  
<223> Description of Artificial Sequence:primer for  
amplifying kanamycin resistant gene of  
40 Streptococcus faecalis

<400> 1  
45 cccgttaact gcttgaaacc caggacaata ac 32

50

55

EP 1 154 020 A2

5 <210> 2  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> Description of Artificial Sequence:primer for  
 amplifying kanamycin resistant gene of  
 Streptococcus faecalis

15 <400> 2  
 cccgtaaca tgtacttcag aaaagattag 30

20 <210> 3  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

25 <220>  
 <223> Description of Artificial Sequence:primer for  
 amplifying Escherichia coli cloning vector pHSG399

30 <400> 3  
 gatatctacg tgccgatcaa cgtctc 26

35 <210> 4  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

40 <220>  
 <223> Description of Artificial Sequence:primer for  
 amplifying Escherichia coli cloning vector pHSG399

45 <400> 4  
 aggcttttt ttaaggcagt tattg 25

50 <210> 5  
 <211> 4447  
 <212> DNA  
 <213> Brevibacterium lactofermentum

55

EP 1 154 020 A2

<220>

<221> CDS

<222> (1318)..(2598)

<400> 5

```

aagcttgtct acgtctgatg ctttgaatcg gacggacttg ccgatcttgt atgcggtgat 60
ttttccctcg ttgcccact ttttaatgt ggccggggtg agagctacgc gggcggcgac 120
ctgctgcgct gtgatccaat attcggggtc gttcactggt tcccccttct gatttctggc 180
atagaagaac ccccgtagaac tgtgtgggtc cgggggttgc tgatttttgc gagacttctc 240
gcgcaattcc ctagcttagg tgaaaacacc atgaaacact agggaaacac ccatgaaaca 300
cccattaggg cagtagggcg gcttcttctg ctagggcttg catttgggcg gtgatctggt 360
ctttagcgtg tgaagtgtg tcgtagggtg cgtgctcaat gcactcgaac gtcacgtcat 420
ttaccgggtc acggtgggca aagagaacta gtgggttaga catgttttc ctcgttgctg 480
gtggttggtg gcttttctag ccgctcggta aacgcggcga tcatgaactc ttggagggtt 540
tcaccgttct gcctgcctgc gcgcttcctg tcctcacgta gtgccaaagg aacgcgtgcg 600
gtgaccacga cgggcttagc ctttgctgct gcttctagt ctcgatggt ggcttgtgcc 660
tgcgcttgct gcgctgtgag tgctgttga gcttcttga gtgtgttgc tagctgtgcc 720
ttggttgcca tgccttaaga ctctagtagc ttctctgcga tatgtcatgc gcctgcgtag 780
caaacattgt cctgcaactc attcattatg tgcagtgtc ctgttactag tcgtacatac 840
tcataattac ctagtctgca tgcagtgcac gcacatgcag tcatgtcgtg ctaatgtgta 900
aaacatgtac atgcagattg ctgggggtgc agggggcgga gccacctgt ccatgcgggg 960
tgtggggctt gcccgccggg tacagacagt gagcaccggg gcacctagtc gcggataccc 1020
cccctaggta tcggacacgt aacctccca tctcgatgca aatctttaac attgagtacg 1080
ggtaagctgg cagcatagc caagctaggc ggccaccaa caccactaaa aattaatagt 1140
ccctagacaa gacaaacccc cgtgcgagct accaactcat atgcacgggg gccacataac 1200
ccgaagggtt tcaattgac aacctatgca ctagctaaga caacgggcac aacaccgcga 1260
caaaactcga ctgcgcaacc ccgcacaaca tcgggtctag gtaacactga aatagaa 1317
gtg aac acc tct aag gaa ccg cag gtc aat gag ggt tct aag gtc act 1365
Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr
    1          5          10         15
cgc gct agg gcg tgg cgt agg caa aac gtc atg tac aag atc acc aat 1413
Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn
    20         25         30
agt aag gct ctg gcg ggg tgc cat agg tgg cgc agg gac gaa gct gtt 1461
Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val
    35         40         45
gcg gtg tcc tgg tgc tct aac ggt gct tgc cag ttt gag ggt ctg caa 1509
Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln
    50         55         60
aac tct cac tct cgc tgg ggg tca cct ctg gct gaa ttg gaa gtc atg 1557

```

**EP 1 154 020 A2**

	Asn Ser His Ser Arg Trp Gly Ser Pro Leu Ala Glu Leu Glu Val Met	
	65 70 75 80	
5	ggc gaa cgc cgc att gag ctg gct att gct act aag aat cac ttg gcg Gly Glu Arg Arg Ile Glu Leu Ala Ile Ala Thr Lys Asn His Leu Ala	1605
	85 90 95	
10	gcg ggt ggc gcg ctc atg atg ttt gtg ggc act gtt cga cac aac cgc Ala Gly Gly Ala Leu Met Met Phe Val Gly Thr Val Arg His Asn Arg	1653
	100 105 110	
	tca cag tca ttt gcg cag gtt gaa gcg ggt att aag act gcg tac tct Ser Gln Ser Phe Ala Gln Val Glu Ala Gly Ile Lys Thr Ala Tyr Ser	1701
15	115 120 125	
	tcg atg gtg aaa aca tct cag tgg aag aaa gaa cgt gca cgg tac ggg Ser Met Val Lys Thr Ser Gln Trp Lys Lys Glu Arg Ala Arg Tyr Gly	1749
20	130 135 140	
	gtg gag cac acc tat agt gac tat gag gtc aca gac tct tgg gcg aac Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn	1797
	145 150 155 160	
25	ggg tgg cac ttg cac cgc aac atg ctg ttg ttc ttg gat cgt cca ctg Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu	1845
	165 170 175	
30	tct gac gat gaa ctc aag gcg ttt gag gat tcc atg ttt tcc cgc tgg Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp	1893
	180 185 190	
	tct gct ggt gtg gtt aag gcc ggt atg gac gcg cca ctg cgt gag cac Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His	1941
35	195 200 205	
	ggg gtc aaa ctt gat cag gtg tct acc tgg ggt gga gac gct gcg aaa Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys	1989
40	210 215 220	
	atg gca acc tac ctc gct aag ggc atg tct cag gaa ctg act ggc tcc Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser	2037
	225 230 235 240	
45	gct act aaa acc gcg tct aag ggg tgc tac acg ccg ttt cag atg ttg Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu	2085
	245 250 255	
50	gat atg ttg gcc gat caa agc gac gcc ggc gag gat atg gac gct gtt Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val	2133
	260 265 270	
	ttg gtg gct cgg tgg cgt gag tat gag gtt ggt tct aaa aac ctg cgt Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg	2181
55	275 280 285	

EP 1 154 020 A2

tcg tcc tgg tca cgt ggg gct aag cgt gct ttg ggc att gat tac ata 2229  
 Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile  
 290 295 300  
 5 gac gct gat gta cgt cgt gaa atg gaa gaa gaa ctg tac aag ctc gcc 2277  
 Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala  
 305 310 315 320  
 10 ggt ctg gaa gca ccg gaa cgg gtc gaa tca acc cgc gtt gct gtt gct 2325  
 Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala  
 325 330 335  
 15 ttg gtg aag ccc gat gat tgg aaa ctg att cag tct gat ttc gcg gtt 2373  
 Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val  
 340 345 350  
 agg cag tac gtt cta gat tgc gtg gat aag gct aag gac gtg gcc gct 2421  
 Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala  
 20 355 360 365  
 gcg caa cgt gtc gct aat gag gtg ctg gca agt ctg ggt gtg gat tcc 2469  
 Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser  
 25 370 375 380  
 acc ccg tgc atg atc gtt atg gat gat gtg gac ttg gac gcg gtt ctg 2517  
 Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu  
 385 390 395 400  
 30 cct act cat ggg gac gct act aag cgt gat ctg aat gcg gcg gtg ttc 2565  
 Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe  
 405 410 415  
 gcg ggt aat gag cag act att ctt cgc acc cac taaaagcggc ataaaccccg 2618  
 35 Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His  
 420 425  
 ttccgatattt tgtgcgatga atttatggtc aatgtcgcgg gggcaaaacta tgatgggtct 2678  
 40 tgttgttgac aatggctgat ttcatacagga atggaactgt catgctgtta tgtgcctggc 2738  
 tcctaatacaa agctggggac aatgggttgc cccgttgatc tgatctagtt cggattggcg 2798  
 gggcttcact gtatctgggg gtggcatcgt gaatagattg cacaccgtag tgggcagtgt 2858  
 gcacaccata gtggcatga gtaataccta cgcgcgcgtg ggctagggt taacgcgcgt 2918  
 45 ttgccgtgc tgcggggcat acgttagcgc atacgtttt ttctgtgaaa cttttttgtg 2978  
 ttgttgtttc gtgttggttt cttttctgtt ggcggggcaa cttaacgcct gcgggggttg 3038  
 ttgttgacgt taacgggggt agtttttatt cccctagtgg tttttcagta cgacaatcga 3098  
 gaaagacctg tticagccag ttcgggtcat gttcgtcgt atggccact gcatagcgac 3158  
 50 cagttttcga gticactggg atttttggtg catcgaacaa gatgtaggac aatgcggtt 3218  
 ctaggcttac tttttgctt atgccgtaca agccccgtg gtattcagcg attgattcca 3278  
 agcgcgcttc ccagtcctgt ttgtgaagg actggcttag ttctaggtct gtgtctgggt 3338  
 agtactgctt gtttgttaa gcgccgttg tgcctattga tgattcctt gaagtgttg 3398  
 55 gatttcggct agtagtcgg cgtatgtgc tgccttttgc tcgtgatagc tcgccttggc 3458

EP 1 154 020 A2

tatgaggtcg gctaggtagg tticcggggt gcctaggttg cgtaggtcta gcaaattccc 3518  
 gtatgtggcc tgtgcgctgc gctggtggtg catacagtcg ttaagctggg cttttacgtc 3578  
 5 tgcgatgcgg tggcggttag gcatgttggt gtgcttcttc caagtactca cgggcggggt 3638  
 ttgtgtatgc ctggcgtgat gcttctttga gctgttgag ttccgcttgg agtgcgggta 3698  
 gttcgtccgc gaactgcttg tggtaactcgt atttctcttg ttccctgggcg atagcatttg 3758  
 cgttgaattg cagggcggtg agttcgtcca cgcgtcgttt tgctgcgttg gtcattggtg 3818  
 10 cgtgccattt gcggttggtg acgcggggtt caaggttgcg cacggctgct tcggctaggt 3878  
 tggtagctgc tttttcagt gctcgggctt cccgttcttc gtccaacgag agcaccittg 3938  
 gtttgttggc ttccgctagt ttttgcctct ccgcttggat gagttggtca acttcgtgtt 3998  
 gggagaggtc gtttttcacg atgcgtcgaa tgtggtcgtt gtgggtgctg agttggtgtg 4058  
 15 agaggtagtg gggttctggg atttcggcga gttggtcgag gttggttag tgcgggttgc 4118  
 ggctgtgtg gttgggttcg ctggggaggt cgaatgatcc ggttgagtct ccggcgtggt 4178  
 tgaagtgaat taggcgttgg tagccgtatt cctggttggg gaggtacgac agaattagga 4238  
 agtttgggtc ttctcctgca atgagtcgtg cgtgttcgta gttcgggtact gggtcgtgct 4298  
 20 cggggagaaat gttcttttgg gtcattggtt cttcttctgt tgctctgtaa gtccgtatgt 4358  
 gggcatggga aagccccggc aaccctttgg gtcaaccggg gctagatagt cgcttagaat 4418  
 ggcttctagg ctgcgtctcg ggggtggtc 4447

<210> 6

<211> 427

<212> PRT

<213> Brevibacterium lactofermentum

<400> 6

Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr  
 1 5 10 15  
 Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn  
 20 25 30  
 Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val  
 35 40 45  
 Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln  
 50 55 60  
 Asn Ser His Ser Arg Trp Gly Ser Pro Leu Ala Glu Leu Glu Val Met  
 65 70 75 80  
 Gly Glu Arg Arg Ile Glu Leu Ala Ile Ala Thr Lys Asn His Leu Ala  
 85 90 95  
 50 Ala Gly Gly Ala Leu Met Met Phe Val Gly Thr Val Arg His Asn Arg  
 100 105 110  
 Ser Gln Ser Phe Ala Gln Val Glu Ala Gly Ile Lys Thr Ala Tyr Ser  
 115 120 125  
 55 Ser Met Val Lys Thr Ser Gln Trp Lys Lys Glu Arg Ala Arg Tyr Gly

EP 1 154 020 A2

	130	135	140
	Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn		
5	145	150	155 160
	Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu		
	165	170	175
	Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp		
10	180	185	190
	Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His		
	195	200	205
	Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys		
15	210	215	220
	Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser		
	225	230	235 240
20	Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu		
	245	250	255
	Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val		
	260	265	270
25	Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg		
	275	280	285
	Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile		
	290	295	300
30	Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala		
	305	310	315 320
	Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala		
	325	330	335
35	Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val		
	340	345	350
	Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala		
	355	360	365
40	Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser		
	370	375	380
	Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu		
45	385	390	395 400
	Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe		
	405	410	415
	Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His		
50	420	425	

<210> 7

<211> 4447

55 <212> DNA



EP 1 154 020 A2

<213> Brevibacterium lactofermentum

<220>

<221> CDS

<222> (1318)..(2598)

<400> 7

```

aagcttgctc acgtctgatg ctttgaatcg gacggacttg ccgatcttgt atgcggtgat 60
ttttccctcg ttgtcccaact ttttaatggt ggccgggggtg agagctacgc gggcggcgac 120
ctgctgcgct gtgatccaat attcggggtc gttcactggt tcccctttct gatttctggc 180
atagaagaac ccccgtgaac tgtgtggttc cgggggttgc tgatttttgc gagacttctc 240
gcgcaattcc ctacttagg tgaaacacc atgaaacact agggaaacac ccatgaaaca 300
cccattaggg cagtaggcgc gcttcttctg ctaggccttg catttgggcg gtgactcgtg 360
ctttagcgtg tgaagtggtg tcgtaggtag cgtgtcaat gcactcgaac gtcacgtcat 420
ttaccgggtc acggtgggca aagagaacta gtgggttaga cattgttttc ctcgttctcg 480
gtggtggtga gcttttctag ccgctcggta aacgcgcgca tcatgaactc ttggaggttt 540
tcaccgttct gcatgcctgc gcgcttcagt tcctcacgta gtgcaaagg aacgcgtgcg 600
gtgaccacga cgggcttagc ctttgctgc gcttctagt cttcgatggt ggcttgtgcc 660
tgcgcttctg gcgctgtag tgcctgtga gcttcttcta gttgctgttc tagctgtgcc 720
ttggttgcca tgccttaaga ctctagtagc tttcctgcga tatgtcatgc gcatgcgtag 780
caaacattgt cctgcaactc attcattatg tgcagtgtc ctgttactag tcgtacatac 840
tcatatttac ctagtctgca tgcagtcat gcacatgcag tcatgtcgtg ctaatgtgta 900
aaacatgtac atgcagattg ctgggggtgc agggggcgga gccacctgt ccatgcgggg 960
tgtggggctt gccccgcgg tacagacagt gacacccggg gcacctagtc gcggataccc 1020
cccctaggta tcggacacgt aacctcctcca tgcgatgca aatctttaac attgagtacg 1080
ggtaaacttg cagcgaatgc caagctaggg ggccacacaa caccactaaa aattaatagt 1140
tcctagacaa gacaaacccc cgtgcgagct accaactcat atgcacgggg gccacataac 1200
ccgaaggggt ttcaattgac aaccatagca ctagctaaga caacgggcac aacatccgca 1260
caaaactgca ctgcgcaacc ccgcacaaca tcgggtctag gtaacactga aatagaa 1317
gtg aac acc tct aag gaa ccg cag gtc aat gag ggt tct aag gtc act 1365
Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr
      1           5           10           15
cgc gct agg gcg tgg cgt agg caa aac gtc atg tac aag atc acc aat 1413
Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn
      20           25           30
agt aag gct ctg gcg ggg tgc cat agg tgg cgc agg gac gaa gct gtt 1461
Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val
      35           40           45
gcg gtg tcc tgg tgc tct aac ggt gct tgc cag ttt gag ggt ctg caa 1509
Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln
      50           55           60

```

**EP 1 154 020 A2**

	aac tct cac tct cgc tgg ggg tca tct ctg gct gaa ttg gaa gtc atg	1557
	Asn Ser His Ser Arg Trp Gly Ser Ser Leu Ala Glu Leu Glu Val Met	
5	65 70 75 80	
	ggc gaa cgc cgc att gag ctg gct att gct act aag aat cac ttg gcg	1605
	Gly Glu Arg Arg Ile Glu Leu Ala Ile Ala Thr Lys Asn His Leu Ala	
	85 90 95	
10	gcg ggt ggc gcg ctc atg atg ttt gtg ggc act gtt cga cac aac cgc	1653
	Ala Gly Gly Ala Leu Met Met Phe Val Gly Thr Val Arg His Asn Arg	
	100 105 110	
15	tca cag tca ttt gcg cag gtt gaa gcg ggt att aag act gcg tac tct	1701
	Ser Gln Ser Phe Ala Gln Val Glu Ala Gly Ile Lys Thr Ala Tyr Ser	
	115 120 125	
	tcg atg gtg aaa aca tct cag tgg aag aaa gaa cgt gca cgg tac ggg	1749
20	Ser Met Val Lys Thr Ser Gln Trp Lys Lys Glu Arg Ala Arg Tyr Gly	
	130 135 140	
	gtg gag cac acc tat agt gac tat gag gtc aca gac tct tgg gcg aac	1797
	Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn	
25	145 150 155 160	
	ggt tgg cac ttg cac cgc aac atg ctg ttg ttc ttg gat cgt cca ctg	1845
	Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu	
	165 170 175	
30	tct gac gat gaa ctc aag gca ttt gag gat tcc atg ttt tcc cgc tgg	1893
	Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp	
	180 185 190	
35	tct gct ggt gtg gtt aag gcc ggt atg gac gcg cca ctg cgt gag cac	1941
	Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His	
	195 200 205	
40	ggg gtc aaa ctt gat cag gtg tct acc tgg ggt gga gac gct gcg aaa	1989
	Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys	
	210 215 220	
	atg gca acc tac ctc gct aag ggc atg tct cag gaa ctg act ggc tcc	2037
	Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser	
45	225 230 235 240	
	gct act aaa acc gcg tct aaa ggg tcg tac acg ccg ttt cag atg ttg	2085
	Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu	
	245 250 255	
50	gat atg ttg gcc gat caa agc gac gcc ggc gag gat atg gac gct gtt	2133
	Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val	
	260 265 270	
55	ttg gtg gct cgg tgg cgt gag tat gag gtt ggt tct aaa aac ctg cgt	2181
	Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg	

EP 1 154 020 A2

275 280 285  
 tcg tct tgg tca cgt ggg gct aag cgt gct ttg ggc att gat tac ata 2229  
 5 Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile  
 290 295 300  
 gac gct gat gta cgt cgt gaa atg gaa gaa gaa ctg tac aag ctc gcc 2277  
 Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala  
 10 305 310 315 320  
 ggt ctg gaa gca ccg gaa cgg gtc gaa tca acc cgc gtt gct gtt gct 2325  
 Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala  
 325 330 335  
 15 ttg gtg aag ccc gat gat tgg aaa ctg att cag tct gat ttc gcg gtt 2373  
 Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val  
 340 345 350  
 20 agg cag tac gtt cta gat tgc gtg gat aag gct aag gac gtg gcc gct 2421  
 Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala  
 355 360 365  
 gcg caa cgt gtc gct aat gag gtg ctg gca agt ctg ggt gtg gat tcc 2469  
 25 Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser  
 370 375 380  
 acc ccg tgc atg atc gtt atg gat gat gtg gac ttg gac gcg gtt ctg 2517  
 Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu  
 30 385 390 395 400  
 cct act cat ggg gac gct act aag cgt gat ctg aat gcg gcg gtg ttc 2565  
 Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe  
 405 410 415  
 35 gcg ggt aat gag cag act att ctt cgc acc cac taaaagcggc ataaaccccg 2618  
 Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His  
 420 425  
 40 ttcgatattt tgtgcgatga atttatggtc aatgtcgcgg gggcaacta tgatgggtct 2678  
 tgttgttgac aatggctgat ttcacagga atggaactgt catgctgta tgtgcctggc 2738  
 tcctaatcaa agctggggac aatgggttgc cccgttgatc tgatctagtt cggattggcg 2798  
 gggcttcact gtaactgggg gtggcatcgt gaatagattg cacaccgtag tgggcagtgt 2858  
 45 gcacaccata gtgggcatga gtaataccta cgcgcgcgtg ggctagggct taacgcgcgt 2918  
 ttgcccgtgc tgcggggcat acgttagcgc atacgctttt ttctgtgaaa cctttttgtg 2978  
 ttgttgttgc gtgttggttt cttttctgtt ggcggggcaa cttaacgcct gcgggggtgg 3038  
 ttgttgacgt taacgggggt agtttttatt cccctagtgg tttttcagta cgacaatcga 3098  
 50 gaaagacctg tttcagccag ttcgggtcat gttcgtcggg atggccacgt gcatagcgac 3158  
 cagttttcga gttcactggg atttttggtg catcaaacaa gatgtaggac aatgcggttt 3218  
 ctaggctctac tttttgcttt atgccgtaca agccccgtgg gtattcagcg attgattcca 3278  
 aggcggcttc ccagtcctgt tttgtgaagg actggcttag ttctaggtct gtgtctgggt 3338  
 55 agtactgctt gtttgtgtaa gcgccgttgg tgctcattga tgattccttt gaagtgtttg 3398

EP 1 154 020 A2

5 gagttcggct agtagtgcgg cgtatggtgc tgctttttgc tcgtgatagc tcgccttggc 3458  
 tatgaggtcg gctaggtagg ttccgggggt gcctaggttg ctaggtcta gcaaatcccg 3518  
 gtatgtggcc tgtgcgtgc gctggtggg catacagtcg ttaagctggg cttttacgtc 3578  
 tgcgatgcgg tggcggttag gcatgttgg gtgcttcttc caagtactca cgggcgggtt 3638  
 ttgtgtatgc ctggcgtgat gcttctttga gctgttgag ttccgcttg agtgcgggta 3698  
 gttcgtccgc gaactgcttg tggactcgt atttctcttg ttccgtggcg atagcatttg 3758  
 10 cgttgaattg caggcggtg agttcgtcca cgcgtcgtt tgctgcgttg gtcattggtg 3818  
 cgtgccattt gcggttggg acgcgggggt caaggttgcg caggtcgtc tcggctaggt 3878  
 tgggtggtgc ttttttcagt gctcgggctt cccgttctc gtccaacgag agcacctttg 3938  
 gtttgttggc ttccgctagt ttttcttct ccgcttgat gatttggta acttcgtgtt 3998  
 15 gggagaggtc gtttttcacg atgcgtcgaa tgggtcgtt ggggtgctg agttggtgtg 4058  
 agaggtagt gggttctggg atttcggcga gttggtcgag gttggttag tgcgggttgc 4118  
 ggcttggtg gttgggttcg ctggggaggt ccatgtatcc ggttgcgtc ccggcgtggt 4178  
 tgaagtgaat tagcggttg tagccgtatt cctggttggg gaggtacgac agaattgagga 4238  
 20 agtttgggtc ttctcctgca atgagtcgtg cgtgttcgta gttcgttact gggtcgtgct 4298  
 cggggagaat gttcttttgg gtcattggct ctctttctgt tgctctgtaa gtccgtatgt 4358  
 gggcatggga aagccccggc aaccttttgg gtcaaccggg gctagatagt cgcttagaat 4418  
 25 ggcttctagg ctgcgtctcg ggggtggtc 4447

<210> 8

<211> 427

<212> PRT

<213> Brevibacterium lactofermentum

<400> 8

35 Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr  
 1 5 10 15  
 Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn  
 20 25 30  
 40 Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val  
 35 40 45  
 Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln  
 50 55 60  
 45 Asn Ser His Ser Arg Trp Gly Ser Ser Leu Ala Glu Leu Glu Val Met  
 65 70 75 80  
 Gly Glu Arg Arg Ile Glu Leu Ala Ile Ala Thr Lys Asn His Leu Ala  
 85 90 95  
 50 Ala Gly Gly Ala Leu Met Met Phe Val Gly Thr Val Arg His Asn Arg  
 100 105 110  
 55 Ser Gln Ser Phe Ala Gln Val Glu Ala Gly Ile Lys Thr Ala Tyr Ser  
 115 120 125

EP 1 154 020 A2

Ser Met Val Lys Thr Ser Gln Trp Lys Lys Glu Arg Ala Arg Tyr Gly  
 130 135 140  
 5 Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn  
 145 150 155 160  
 Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu  
 165 170 175  
 10 Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp  
 180 185 190  
 Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His  
 195 200 205  
 15 Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys  
 210 215 220  
 Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser  
 225 230 235 240  
 20 Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu  
 245 250 255  
 Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val  
 260 265 270  
 25 Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg  
 275 280 285  
 Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile  
 290 295 300  
 30 Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala  
 305 310 315 320  
 Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala  
 325 330 335  
 35 Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val  
 340 345 350  
 Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala  
 355 360 365  
 40 Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser  
 370 375 380  
 Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu  
 385 390 395 400  
 Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe  
 405 410 415  
 50 Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His  
 420 425  
 <210> 9  
 55 <211> 30

EP 1 154 020 A2

<212> DNA

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence:primer for  
introducing mutation to pAM330

10

<400> 9

aaaccgggc tacgtctgat gcttgaatc

30

15

<210> 10

<211> 27

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:primer for  
introducing mutation to pAM330

25

<400> 10

tttgatcccc cgtaacgta aacaacc

27

30

<210> 11

<211> 28

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:primer for  
introducing mutation to pAM330

40

<400> 11

ttttccggg agcttgccac accccgag

28

45

<210> 12

<211> 24

<212> DNA

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence:primer for  
introducing mutation to pAM330

55

5 <400> 12  
gggggtcatc tctggctgaa ttgg 24

<210> 13  
<211> 24  
10 <212> DNA  
<213> Artificial Sequence

<220>  
15 <223> Description of Artificial Sequence:primer for  
introducing mutation to pAM330

20 <400> 13  
gaggttttca ccgttctgca tgcc 24

<210> 14  
25 <211> 23  
<212> DNA  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence:primer for  
introducing mutation to pAM330

35 <400> 14  
aactcaccgc cctgcaattc aac 23

40 <210> 15  
<211> 25  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence:primer for PCR

50 <400> 15  
gcctaccgcg gcaaagaagt ggcag 25

55 <210> 16  
<211> 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

5

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:primer for PCR

10

&lt;400&gt; 16

gccttgaact aggggcgctt taagt

25

&lt;210&gt; 17

15

&lt;211&gt; 4235

&lt;212&gt; DNA

&lt;213&gt; Brevibacterium flavum

20

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1852)..(2364)

25

&lt;400&gt; 17

aaaccgggt ttcttctgc aactcgggcg ccgaagcaaa cgaggctgct ttcaagattg 60  
 cacgcttgac tggctgtcc cggattctgg ctgcagtcca tggtttcac ggccgcacca 120  
 tgggttcctt cgcgctgact ggccagccag acaagcgtga agcgttcctg ccaatgccaa 180  
 gcggtgtgga gttctacct tacggcgaca ccgattactt gcgcaaaatg gtagaaacca 240  
 acccaacgga tgtggtgct atcttctcg agccaatcca gggtgaaacg ggcgttggtc 300  
 cagcacctga aggattcctc aaggcagtcg gcgagctgtg cgatgagtac ggcattctga 360  
 tgatcaccca tgaagtcag actggcgttg gccgtaccgg cgatttcttt gcacatcagc 420  
 acgatggcgt tgtcccgat gtggtgacca tggccaaggg acttggcggc ggtcttccca 480  
 tcggtgcttg ttggccaact ggccgtgcag ctgaattgat gacccagcgc aagcacggca 540  
 ccaatttcgg tggcaaccca gttgcttggt cagctgcca ggacagtgct tctgttgtcg 600  
 atgacgcttt ctgcgcagaa gttaccgcga agggcgagct gttcaagta cttcttgcca 660  
 aggttgacgg cgtgtgtagc gtccgtggca gggccttgat gttggcgtg gtgctggagc 720  
 gcgacgtcgc aaagcaagct gttcttgatg gttttaagca cggcgttatt tgaatgcac 780  
 cgccggacaa cattatccgt ttgacccgcg cgctggtgat caccgacgaa gaaatcgag 840  
 acgcagtcga ggctattgcc gagacaatcg cataaaggac ttaaacttat gacttcacaa 900  
 ccacaggttc gccatttctt ggctgatgat gatctaccc ctgcagagca ggcagagggt 960  
 ttgaccctag ccgcaaaagt caaggcagcg ccgttttcgg agcgtccact cgagggacca 1020  
 aagtcggttg cagttctttt tgataagact tcaactegta ctgcttctc cttegacgcg 1080  
 ggcatcgctc atttgggtgg acatgccatc gtcgtggatt ccggcagctc acagatgggt 1140  
 aagggcgaga ccctgcagga caccgcagct gtattgtccc gctacgtgga agcaattgtg 1200  
 tggcgacact acgcacacag caatttcac gccatggcgg agacgtccac tgtgccgctg 1260  
 gtgaactcct tgtccgatga tctgcacca tgccagattc tggctgatct gcagaccatc 1320

55



EP 1 154 020 A2

gtggaaaacc tcagccctga agaaggccca gcaggcctta agggtaagaa ggctgtgtac 1380  
ctgggcgatg gcgacaaca catggccaac tectacatga ttggctttgc caccgcgggc 1440  
5 atggatattt ccatcatcgc tctgaaggg ttccagcctc gtgcggaatt cgtggagcgc 1500  
gcggaaaagc gtggccagga aaccggcgcg aaggttggtg tcaccgacag cctcgacgag 1560  
gttcccgcg ccatgttgt catcaecgat acctgggtat ccatgggtat gaaaacgac 1620  
ggcatcgtc gcaccacacc ttctgttct taccaggtca acgatgaggt catggcgaaa 1680  
10 gctaacgagc gcgccatctt cctgcactgc cttcctgcct acccgcgcaa agaagtggca 1740  
gcctccgtga ttgatggacc agcgtccaaa gttttcgtg aagcagaaaa ccgcctccac 1800  
gctcagaaag cactgctggt gtgctgctg gcccaaccagc cgagtaaga c atg tct 1857  
Met Ser  
15  
1  
ctt ggc tca acc cgc tca aca cgc gaa aac tta aat ccc gtg act cgc 1905  
Leu Gly Ser Thr Pro Ser Thr Pro Glu Asn Leu Asn Pro Val Thr Arg  
5 10 15  
20 act gca cgc caa gct ctc att ttg cag att ttg gac aaa caa aaa gtc 1953  
Thr Ala Arg Gln Ala Leu Ile Leu Gln Ile Leu Asp Lys Gln Lys Val  
20 25 30  
25 acc agc cag gta caa ctg tct gaa ttg ctg ctg gat gaa ggc atc gat 2001  
Thr Ser Gln Val Gln Leu Ser Glu Leu Leu Leu Asp Glu Gly Ile Asp  
35 40 45 50  
30 atc acc cag gcc acc ttg tcc cgg gat ctc gat gaa ctc ggt gca cgc 2049  
Ile Thr Gln Ala Thr Leu Ser Arg Asp Leu Asp Glu Leu Gly Ala Arg  
55 60 65  
aag gtt cgc ccc gat ggg gga cgc gcc tac tac gcg gtc ggc cca gta 2097  
Lys Val Arg Pro Asp Gly Gly Arg Ala Tyr Tyr Ala Val Gly Pro Val  
35 70 75 80  
gat agc atc gcc cgc gaa gat ctc cgg ggt ccg tcg gag aag ctg cgc 2145  
Asp Ser Ile Ala Arg Glu Asp Leu Arg Gly Pro Ser Glu Lys Leu Arg  
40 85 90 95  
cgc atg ctt gat gaa ctg ctg gtt tct aca gat cat tcc ggc aac atc 2193  
Arg Met Leu Asp Glu Leu Leu Val Ser Thr Asp His Ser Gly Asn Ile  
100 105 110  
45 gcg atg ctg cgc acc ccg ccg gga gct gcc cag tac ctg gca agt ttc 2241  
Ala Met Leu Arg Thr Pro Pro Gly Ala Ala Gln Tyr Leu Ala Ser Phe  
115 120 125 130  
atc gat agg gtg ggg ctg aaa gaa gtc gtt ggc acc atc gct ggc gat 2289  
50 Ile Asp Arg Val Gly Leu Lys Glu Val Val Gly Thr Ile Ala Gly Asp  
135 140 145  
gac acc gtt ttt gtt ctc gcc cgt gat ccg ctc aca ggt aaa gaa cta 2337  
Asp Thr Val Phe Val Leu Ala Arg Asp Pro Leu Thr Gly Lys Glu Leu  
55 150 155 160

EP 1 154 020 A2

ggt gaa tta ctc agc ggg cgc acc act taaagcgccc ctagtccaag 2384  
Gly Glu Leu Leu Ser Gly Arg Thr Thr

165

170

gcttgtaaat cgcttgtaa tgcaggcagg taaggtataa cccgagtgtt ttttcgagga 2444  
ataccaaccc tttaacaca ataattttct ttaaacaatcc ttgctgtcca ccacggctgg 2504  
caaggaactt aaaatgaagg agcacacctc atgactaacc gcacgtttct tgcatactcc 2564  
ggcggctcgg acaccactgt ggcaattcca tacctgaaga agatgattga tggatgaagtc 2624  
atcgacgttt ctctcgacct ggccagggtt ggagagaaca tggacaacgt tgcacagcgt 2684  
gcattggatg cgggtgcagc tgagtcacat gttgttgatg caaaggatga gttcgtcag 2744  
gagtactgcc tgccaacat caaggcaaac ggcatgtaca tgaagcagta cccactggtt 2804  
cttgcattct cccgcccaet gatcgtcaag caccctgttg aggctggcaa gcagttcaac 2864  
ggtacccacg ttgcacacgg ctgcactggt aaggccaacg accaggttcg tttcgaggtc 2924  
ggcttcatgg acaccgatcc aaacctggag atcattgcac ctgctcgtga cttcgcattg 2984  
accgcgaca aggcattcgc cttcgccgag gagaacaacg ttccaatcga gcagtcctg 3044  
aagtcctcat tctccatcga ccagaacgct tggggccgag ctattgagac cggttacctg 3104  
gaagatctgt ggaatgtcc aaccaaggac atctacgcat acaccgagga tccagctctg 3164  
ggtaacgctc cagatgaggt catcatctcc ttcgagggtg gcaagccagt ctccatcgat 3224  
ggcgtccag tctccgtact gcaggttatt gaagagctga accgtcgtgc aggcgcacag 3284  
ggcgttggcc gccttgacat ggttgaggac cgtctcgtgg gcatacaagc ccgcgaaatc 3344  
tacgaagcac caggcgcaat cgcactgatt aaggtcacg aggccttgga agatgtcacc 3404  
atcgagcgag aactggctcg ctacaagcgt ggcttgacg caggttgggc tgaggaaagta 3464  
tacgacggcc tgtggttcgg acctctgaag cgctccctgg acgcgttcat tgattccacc 3524  
caggagcagc tcaccggcga taccgcatg gttctgcacg caggttccat caccatcaat 3584  
ggtcgtcgtt ccagccactc cctgtacgac ttaaacctgg ctacctacga caccggcgac 3644  
accttcgacc agaccctggc taagggtttt gtccagctgc acggtctgtc ctccaagatc 3704  
gctaacaagc gcgacgcga agctggcaac aactaagcca ccttttcaag catccagact 3764  
agaacttcaa gtatttagaa agtagaagaa caccacatgg aacagcacgg aaccaatgaa 3824  
ggtgcgtgtt gggcgccgag cttctccggt ggaccctccg aggcctggtt cgccttgagt 3884  
gtctccactc atttcgactg ggttttggcc ctttatgatg tgttgccctc caaggcacac 3944  
gccaagggtt tgcaccaagc agagctactt tctgatgaag atctagccac catgctggct 4004  
ggtcttgatc agctgggcaa ggatgtgcc gacggaacct tcggtccgct gccttctgat 4064  
gaggatgtgc acggcgcat ggaacgggt ctgattgacc gcgttggtcc tgagggtggc 4124  
ggcgtctgc gcgtggtcg ttcccgcaac gaccagggtg caacctgtt ccgcatgtg 4184  
gtccgcgacg cagtgcgca catcgctcg ggaacaaccg agcttgcga c 4235

<210> 18

<211> 171

<212> PRT

<213> Brevibacterium flavum

<400> 18

EP 1 154 020 A2

Met Ser Leu Gly Ser Thr Pro Ser Thr Pro Glu Asn Leu Asn Pro Val  
 1 5 10 15  
 5 Thr Arg Thr Ala Arg Gln Ala Leu Ile Leu Gln Ile Leu Asp Lys Gln  
 20 25 30  
 Lys Val Thr Ser Gln Val Gln Leu Ser Glu Leu Leu Leu Asp Glu Gly  
 35 40 45  
 10 Ile Asp Ile Thr Gln Ala Thr Leu Ser Arg Asp Leu Asp Glu Leu Gly  
 50 55 60  
 Ala Arg Lys Val Arg Pro Asp Gly Gly Arg Ala Tyr Tyr Ala Val Gly  
 65 70 75 80  
 15 Pro Val Asp Ser Ile Ala Arg Glu Asp Leu Arg Gly Pro Ser Glu Lys  
 85 90 95  
 Leu Arg Arg Met Leu Asp Glu Leu Leu Val Ser Thr Asp His Ser Gly  
 100 105 110  
 20 Asn Ile Ala Met Leu Arg Thr Pro Pro Gly Ala Ala Gln Tyr Leu Ala  
 115 120 125  
 Ser Phe Ile Asp Arg Val Gly Leu Lys Glu Val Val Gly Thr Ile Ala  
 130 135 140  
 25 Gly Asp Asp Thr Val Phe Val Leu Ala Arg Asp Pro Leu Thr Gly Lys  
 145 150 155 160  
 Glu Leu Gly Glu Leu Leu Ser Gly Arg Thr Thr  
 30 165 170

<210> 19  
 <211> 25  
 35 <212> DNA  
 <213> Artificial Sequence

<220>  
 40 <223> Description of Artificial Sequence:primer for PCR

<400> 19  
 45 cccgggtttt cttctgcaac tcggg 25

<210> 20  
 <211> 25  
 50 <212> DNA  
 <213> Artificial Sequence

<220>  
 55 <223> Description of Artificial Sequence:primer for PCR

<400> 20

5 gtcgacaagc tcggttggtc ccagc 25

<210> 21

<211> 24

10 <212> DNA

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence:primer for PCR

<400> 21

20 cccctagttc aaggttggtt aatc 24

<210> 22

<211> 25

25 <212> DNA

<213> Artificial Sequence

<220>

30 <223> Description of Artificial Sequence:primer for PCR

<400> 22

35 gtcttacctc ggctggttgg ccagc 25

#### Claims

- 45 1. A coryneform bacterium in which an arginine repressor does not function in a normal manner, and which has L-arginine producing ability.
2. The coryneform bacterium according to Claim 1, wherein the arginine repressor does not function in a normal manner due to disruption of a gene coding for the arginine repressor on a chromosome of the bacterium.
- 50 3. The coryneform bacterium according to Claim 2, wherein the arginine repressor has the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence showing homology to the amino acid sequence.
- 55 4. A method for producing L-arginine, which comprises culturing a coryneform bacterium according to any one of Claims 1-3 in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

Fig. 1





Fig. 2






Fig. 3

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 154 020 A3**

(12)

**EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
22.01.2003 Bulletin 2003/04

(51) Int Cl.7: **C12N 15/31, C12N 1/21,**  
**C07K 14/34, C12P 13/10**

(43) Date of publication A2:  
14.11.2001 Bulletin 2001/46

(21) Application number: **01109457.0**

(22) Date of filing: **24.04.2001**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **28.04.2000 JP 2000129167**

(71) Applicant: **Ajinomoto Co., Ltd.**  
**Tokyo (JP)**

(72) Inventors:  
• **Suga, Mikiko, Ajinomoto Co., Inc.**  
**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**

- **Asakura, Yoko, Ajinomoto Co., Inc.**  
**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**
- **Mori, Yukiko, Ajinomoto Co., Inc.**  
**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**
- **Ito, Hisao, Ajinomoto Co., Inc.**  
**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**
- **Kurahashi, Osamu, Ajinomoto Co., Inc.**  
**Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)**

(74) Representative: **HOFFMANN - EITLÉ**  
**Patent- und Rechtsanwälte**  
**Arabellastrasse 4**  
**81925 München (DE)**

(54) **Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine**

(57) L-Arginine is produced by culturing a coryneform bacterium in which an arginine repressor involved in L-arginine biosynthesis is deleted by disrupting a gene coding for the repressor, and which has L-arginine

producing ability in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

**EP 1 154 020 A3**



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 10 9457

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 3 878 044 A (KUBOTA KOJI ET AL) 15 April 1975 (1975-04-15)	1	C12N15/31
Y	* column 1, paragraph 2 - paragraph 4; claims 1,2 *	2-4	C12N1/21
Y	----- DATABASE EMBL 'Online! 6 January 1999 (1999-01-06) KO S.-Y. ET AL.: "Corynebacterium glutamicum arginine repressor (argR) gene, complete cds." retrieved from EBI Database accession no. AF041436 XP002221143 * the whole document *	2-4	C07K14/34
A	----- EP 0 261 627 A (KYOWA HAKKO KOGYO KK) 30 March 1988 (1988-03-30) * page 4, line 15 - line 29 *	1-4	C12P13/10
A	----- EP 0 443 031 A (KYOWA HAKKO KOGYO KK) 28 August 1991 (1991-08-28) * column 1, paragraph 4 *	1-4	
A	----- TIAN G ET AL: "Mutational analysis of the arginine repressor of Escherichia coli." MOLECULAR MICROBIOLOGY. ENGLAND AUG 1994, vol. 13, no. 4, August 1994 (1994-08), pages 599-608, XP008010753 ISSN: 0950-382X * abstract *	1-4	
	----- -/--		
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 19 November 2002	Examiner Gurdjian, D
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons A : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 03/92 (PdeC01)





European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 10 9457

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (InCL17)
A	<p>MESSENGUY F ET AL: "Determination of the DNA-binding sequences of ARGR proteins to arginine anabolic and catabolic promoters."</p> <p>MOLECULAR AND CELLULAR BIOLOGY. UNITED STATES MAY 1991, vol. 11, no. 5, May 1991 (1991-05), pages 2852-2863, XP008010775</p> <p>ISSN: 0270-7306</p> <p>* abstract *</p> <p>-----</p>	1-4	
			<p>TECHNICAL FIELDS SEARCHED (InCL17)</p>
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>19 November 2002</b>	Examiner <b>Gurdjian, D</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>		<p>I : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>A : member of the same patent family, corresponding document</p>	

EP FORM 1503 03 12 (PAC/01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 10 9457

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-11-2002

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 3878044	A	15-04-1975	ES	419433 A1	01-04-1976
EP 0261627	A	30-03-1988	JP	1994602 C	22-11-1995
			JP	7028749 B	05-04-1995
			JP	63079597 A	09-04-1988
			DE	3785530 D1	27-05-1993
			DE	3785530 T2	18-11-1993
			EP	0261627 A2	30-03-1988
			KR	9004425 B1	25-06-1990
			US	5017482 A	21-05-1991
EP 0443031	A	28-08-1991	JP	3183474 A	09-08-1991
			AU	634268 B2	18-02-1993
			AU	6184990 A	08-04-1991
			CA	2041653 A1	05-03-1991
			EP	0443031 A1	28-08-1991
			WO	9103546 A1	21-03-1991
			US	5217888 A	08-06-1993

EPO FORM P0455

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82